Fig. 8: Enhanced tumor regression in a combination therapy of PLD1 inhibitor and αPD-L1 antibody via immune activation.

a Syngeneic mice were subcutaneously injected with MC38-GFP-Luc cells and treated with A3373 (10 mg/kg) and/or αPD-L1 (100 μg/mouse) at once every 2 days. The tumor volume was measured during the indicated period. b Effect of the indicated drug(s) on the tumor weight. c Effect of the indicated drug(s) on the expression of “do not eat-me” and “eat-me” signals as analyzed by IHC. Scale bar, 20 µm. d Effect of the indicated drug(s) on the population of immune cells that infiltrated into tumors, as analyzed by flow cytometry. e Effect of the indicated drug(s) on the phenotyping of macrophages infiltrated into tumors. f Effect of the drug(s) on the population of PD1⁺ and CTLA⁺ CD8⁺ T cells infiltrated into tumors. g Effect of the drug(s) on the population of PD1⁺ and CTLA⁺ CD4⁺ T cells infiltrated into tumors. h Effect of the drug(s) on the CD8⁺ T-cell-mediated killing of MC38-GFP-Luc cancer cells. The results are representative of at least three independent experiments and presented as the means ± SDs. **P < 0.01; ***P < 0.001, n.s. not significant.